NCT06403267View on ClinicalTrials.gov

NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy

PHASE2RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Acute Ischemic Stroke
Interventions
DRUG

NoNO-42

a single dose sterile 20 ml vial containing lyophilized powder for reconstitution containing 300 mg of NoNO-42 active ingredient.

Trial Locations (9)

T2N 2T9

RECRUITING

University of Calgary - Foothills Medical Centre, Calgary

T6G 2B7

RECRUITING

University of Alberta Hospital, Edmonton

V5M 1Z9

RECRUITING

Vancouver General Hospital, Vancouver

R3E 3P5

RECRUITING

University of Manitoba, Winnipeg

L8L 2X2

RECRUITING

Hamilton General Hospital, Hamilton

K1H 8L6

RECRUITING

Ottawa Hospital Research Institute, Ottawa

M4N 3M5

RECRUITING

Sunnybrook Health Sciences Centre, Toronto

M5B 1W8

RECRUITING

Unity Health Toronto, St. Michael's Hospital, Toronto

S7N 0W8

RECRUITING

Royal University Hospital, Saskatoon

All Listed Sponsors
collaborator

University of Calgary

OTHER

lead

NoNO Inc.

INDUSTRY